 phase trial immunoconjug patient cutan t-cell lymphoma immunoconjug chain ricin rta ribosomal-inhibit protein murin monoclon antibodi pan-t-cel antigen antigen cutan t-cell lymphoma tumor cell normal cell lymphocyt phase trial patient cutan t-cell lymphoma progress therapi cycl maxim dose mtd mg/kg/d day dyspnea rest dose other revers side effect myalgia mild hypoalbuminemia weight gain pedal edema fatigu fever chill patient cycl increas side effect first cycl pharmacokinet analysi peak serum drug level dose-depend micrograms/ml termin half-lif hour develop antibodi immunoconjug peak drug level enhanc side effect partial respons month patient respond patient cycl presenc anti-immunoconjug antibodi result phase trial activ drug treatment cutan t-cell lymphoma immunoconjug presenc anti-immunoconjug antibodi respons addit studi mtd respons rate diseas